BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 26805122)

  • 1. [Complete Surgical Resection of a Huge Hepatocellular Carcinoma Invading the Diaphragm and Lung after Transcatheter Arterial Chemoembolization (TACE) and Sorafenib--A Case Report].
    Mukai Y; Wada H; Eguchi H; Tomokuni A; Tomimaru Y; Asaoka T; Kawamoto K; Marubashi S; Umeshita K; Doki Y; Mori M; Nagano H
    Gan To Kagaku Ryoho; 2015 Nov; 42(12):1638-40. PubMed ID: 26805122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [A case of a patient with hepatocellular carcinoma who achieved long-term survival after repeated transcatheter arterial chemoembolization and sorafenib therapy].
    Mukai R; Wada H; Tomimaru Y; Hama N; Kawamoto K; Kobayashi S; Eguchi H; Umeshita K; Doki Y; Mori M; Nagano H
    Gan To Kagaku Ryoho; 2013 Nov; 40(12):1813-5. PubMed ID: 24393931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Successful treatment of metastatic hepatocellular carcinoma with sorafenib combined with transcatheter arterial chemoembolization/hepatic arterial infusion chemotherapy].
    Watanabe Y; Nakaba H; Taniguchi E; Kikkawa H; Tamagawa H; Sasaki M; Kitayama T; Doi Y; Oguchi Y
    Gan To Kagaku Ryoho; 2014 Nov; 41(12):2110-2. PubMed ID: 25731439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complete response with sorafenib and transcatheter arterial chemoembolization in unresectable hepatocellular carcinoma.
    Takano M; Kokudo T; Miyazaki Y; Kageyama Y; Takahashi A; Amikura K; Sakamoto H
    World J Gastroenterol; 2016 Nov; 22(42):9445-9450. PubMed ID: 27895433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retrospective analysis of transarterial chemoembolization and sorafenib in Chinese patients with unresectable and recurrent hepatocellular carcinoma.
    Wan X; Zhai X; Yan Z; Yang P; Li J; Wu D; Wang K; Xia Y; Shen F
    Oncotarget; 2016 Dec; 7(50):83806-83816. PubMed ID: 27566566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival outcomes of hepatic resection compared with transarterial chemoembolization or sorafenib for hepatocellular carcinoma with portal vein tumor thrombosis.
    Lee JM; Jang BK; Lee YJ; Choi WY; Choi SM; Chung WJ; Hwang JS; Kang KJ; Kim YH; Chauhan AK; Park SY; Tak WY; Kweon YO; Kim BS; Lee CH
    Clin Mol Hepatol; 2016 Mar; 22(1):160-7. PubMed ID: 27044767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Two Patients with Recurrence of Hepatocellular Carcinoma after Liver Resection Who Achieved Long-Term Stable Disease with Small Doses of Sorafenib Therapy].
    Kitade H; Yanagida H; Yokoigawa N; Yamada M; Hijikawa T; Kaibori M; Matsui K; Ishizaki M; Yoshioka K; Kon M
    Gan To Kagaku Ryoho; 2015 Jul; 42(7):863-5. PubMed ID: 26197751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The combination of transcatheter arterial chemoembolization and sorafenib is well tolerated and effective in Asian patients with hepatocellular carcinoma: final results of the START trial.
    Chao Y; Chung YH; Han G; Yoon JH; Yang J; Wang J; Shao GL; Kim BI; Lee TY
    Int J Cancer; 2015 Mar; 136(6):1458-67. PubMed ID: 25099027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness analysis of transcatheter arterial chemoembolization with or without sorafenib for the treatment of unresectable hepatocellular carcinoma.
    Zhao RC; Zhou J; Wei YG; Liu F; Chen KF; Li Q; Li B
    Hepatobiliary Pancreat Dis Int; 2017 Oct; 16(5):493-498. PubMed ID: 28992881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overall survival in response to sorafenib with transarterial chemoembolization for BCLC stage B hepatocellular carcinoma: propensity score analysis
.
    Huang Y; Chen B; Liu N; Li N; Dao H; Chen W; Yang J
    Int J Clin Pharmacol Ther; 2017 Jun; 55(6):498-508. PubMed ID: 28157070
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advanced Recurrent Hepatocellular Carcinoma: Treatment with Sorafenib Alone or in Combination with Transarterial Chemoembolization and Radiofrequency Ablation.
    Peng Z; Chen S; Wei M; Lin M; Jiang C; Mei J; Li B; Wang Y; Li J; Xie X; Chen M; Qian G; Kuang M
    Radiology; 2018 May; 287(2):705-714. PubMed ID: 29390197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A case of advanced hepatocellular carcinoma successfully treated by liver resection after complete response induced by sorafenib administration].
    Kim Y; Hosoda Y; Kakita N; Yamada Y; Yamasaki M; Nishino M; Okano M; Nagai K; Yasui M; Tsujinaka T
    Gan To Kagaku Ryoho; 2014 Nov; 41(12):2124-6. PubMed ID: 25731444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Successful Multimodal Treatment for Aggressive Extrahepatic Metastatic Hepatocellular Carcinoma - A Case Report].
    Gon H; Kido M; Fukumoto T; Takebe A; Tanaka M; Kuramitsu K; Kinoshita H; Fukushima K; Urade T; So S; Shinzeki M; Matsumoto I; Ajiki T; Ku Y
    Gan To Kagaku Ryoho; 2015 Sep; 42(9):1111-4. PubMed ID: 26469171
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recurrence-free survival of a hepatocellular carcinoma patient with tumor thrombosis of the inferior vena cava after treatment with sorafenib and hepatic resection.
    Nakamura K; Beppu T; Hayashi H; Okabe H; Imai K; Nitta H; Chikamoto A; Ishiko T; Sasaki M; Baba H
    Int Surg; 2015 May; 100(5):908-14. PubMed ID: 26011214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early prediction of survival in hepatocellular carcinoma patients treated with transarterial chemoembolization plus sorafenib.
    Meng XC; Chen BH; Huang JJ; Huang WS; Cai MY; Zhou JW; Guo YJ; Zhu KS
    World J Gastroenterol; 2018 Jan; 24(4):484-493. PubMed ID: 29398869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Texture analysis of intermediate-advanced hepatocellular carcinoma: prognosis and patients' selection of transcatheter arterial chemoembolization and sorafenib.
    Fu S; Chen S; Liang C; Liu Z; Zhu Y; Li Y; Lu L
    Oncotarget; 2017 Jun; 8(23):37855-37865. PubMed ID: 27911268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sorafenib with TACE improves the survival of hepatocellular carcinoma patients with more than 10 cm tumor: a single-center retrospective study.
    Aktas G; Kus T; Emin Kalender M; Kervancioglu S; Sevinc A; Kul S; Camci C
    J BUON; 2017; 22(1):150-156. PubMed ID: 28365948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the Efficacy of Sorafenib on Overall Survival in Patients with Hepatocellular Carcinoma using FT Rate: A Devised Index.
    Ohki T; Kondo M; Karasawa Y; Kawamura S; Maeshima S; Kojima K; Seki M; Toda N; Shioda Y; Tagawa K
    Adv Ther; 2017 May; 34(5):1097-1108. PubMed ID: 28389996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transarterial chemoembolization and sorafenib in patients with intermediate-stage hepatocellular carcinoma: time to enter routine clinical practice?
    Sacco R; Antonucci M; Bargellini I; Marceglia S; Mismas V; Cabibbo G
    Future Oncol; 2015; 11(17):2371-3. PubMed ID: 26270206
    [No Abstract]   [Full Text] [Related]  

  • 20. TACE Treatment in Patients with Sorafenib-treated Unresectable Hepatocellular Carcinoma in Clinical Practice: Final Analysis of GIDEON.
    Geschwind JF; Kudo M; Marrero JA; Venook AP; Chen XP; Bronowicki JP; Dagher L; Furuse J; Ladrón de Guevara L; Papandreou C; Sanyal AJ; Takayama T; Ye SL; Yoon SK; Nakajima K; Lehr R; Heldner S; Lencioni R
    Radiology; 2016 May; 279(2):630-40. PubMed ID: 26744927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.